Bromodomain and Extra-Terminal Inhibitors Pipeline Analysis 2017

BET Inhibitors Pipeline Analysis

The study analyzed that the BET inhibitors pipeline comprised 38 drug candidates, of which 19 were in Pre-Clinical stage of development. The high prevalence of cancer across the globe fuels the extensive research and development for BET inhibitors. BET inhibitor constitutes that class of drugs, which prevents interactions between BET proteins, and transcription factors and acetylated histone. This results in immunosuppressive and anti-cancer properties of BET inhibitor. Inhibition of BET proteins offered a new therapeutic approach for the treatment of cancer, cardiovascular diseases and other diseases.

Browse the Report Summary at:

As per the findings of the research, around 16% of BET inhibitor drug candidates target BRD4 and 63% of the product candidates target BET. Other targets constituting 21% of candidates of the BET inhibitors pipeline include, but are not limited to, BRD2, BRD3, BRDT, Dual BET/DRD2, PI3K, super enhancer complex (SEC) and JAK2. Around 44% BET inhibitor pipeline drug candidates are being developed to be administered by oral route, and 3% by subcutaneous route.

Explore Report Sample at:

The research finds that different companies are collaborating for the development of BET inhibitors. In January 2017, ConverGene entered into a sponsored research agreement with the University of Maryland, Baltimore. Under this agreement, University of Maryland School of Medicine Professor Curt I. Civin, M.D., who is associate dean for research and director of the Center for Stem Cell Biology & Regenerative Medicine, will investigate the in vivo anti-leukemic effects of ConverGene’s lead BET inhibitor drug candidates, CG223 and CG250. Some of the key players developing BET inhibitors are Resverlogix Corp., GlaxoSmithKline plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AstraZeneca plc, Gilead Sciences, Inc., Zenith Epigenetics Ltd., and Incyte Corporation.


Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Pipeline Analysis – Clinical Trials & Results and Other Developments

Chronic inflammatory demyelinating polyneuropathy pipeline is expected to grow in the next few years on account of increasing prevalence of the disease, which is noticed by progressive muscle weakness, loss of deep tendon reflexes, abnormal sensations, etc. According to a study conducted by American Association of Neuromuscular & Electrodiagnostic Medicine, around 40,000 people in the U.S. get affected from the disease, every year. High prevalence of chronic inflammatory demyelinating polyneuropathy is in turn compelling the government agencies and pharmaceutical companies to promote research and development activities for facilitating growth of the pipeline.

Explore Report at:

Chronic inflammatory demyelinating polyneuropathy is an inflammatory disorder, which affectsthe peripheral nervous system. The diseaseis caused due to the damage of fatty covering myelin sheath that covers and protects nerve fibers.Occurrence of the disease is more common in males as compared to females. Sometimes it is also called as “chronic relapsing polyneuropathy”,whichis closely related to guillain-barre syndrome, because in both the cases the nervous system gets affected. However, in both the cases, the symptoms are not the same for everyone, and can vary from person to person. Some of the common symptoms of the disease includefatigue, pain, weakness, numbness, etc.

Request for Table of Content at:

Some of the companies having a pipeline of chronic inflammatory deyelinating polyneuropathy therapeutic include Shire Inc., LB Biotechnologies., Pfizer Inc., Novartis N.V., Eliy-lilly& Company, Gilead Sciences, Inc., Galapagos NV, Astellas Pharma, Abbvie, Inc., Bexalta US, Inc., Mitsubishi Tanabe Pharma Corporation.

Chronic Myelocytic Leukemia Therapeutics Pipeline Analysis – Collaboration and Other Developments

Chronic myelocytic leukemia therapeutic pipeline analysis is expected to grow rapidly due to the increasing prevalence of the disease, globally. Some of the main factors driving the pipeline analysis for chronic myelocytic leukemia include increasing aging population and rising prevalence of chronic myelocytic leukemia, and increasing health awareness. Chronic myelocytic leukemia have high incidence rate in men and is the second most common type of cancer occurring in male adults. Women, above 50 years of age are at high risk to develop chronic myelocytic leukemia.

Explore Report at:

Chronic myeloid leukemia is the tumour that occurs in blood cells and bone marrow, which is the soft parts inside bones where blood cells are produced. Chronic myelocytic leukemia usually occurs in middle-aged or older adults. It occurs due to the swapping of DNA between chromosome 9 nine and chromosome 22. The resultant abnormal chromosome is known as Philadelphia chromosome. This swapping forms a new gene, BCR-ABL which is the type of protein, tyrosine kinase. This protein causes chronic myelocytic leukemia cells to grow and reproduce uncontrollable manner. One of the main cause of chronic myelocytic leukemia is exposure to high radiation. The symptoms of chronic myelocytic leukemia include stroke, dizziness, change in vision, swollen glands, high fever, bruises, weight loss, pain in bones, short of breath and night sweats. Chronic myeloid leukemia can be diagnosed by performing a bone marrow test, complete blood count, FISH test and ultrasound. The treatment for chronic myeloid leukemia includes drug therapy and stem cell transplant.

Request for Table of Content at:

Some of the companies having a pipeline of chronic myelocytic leukemia therapeutics include Bristol Myers Squibb Company, ARIAD Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Hospira, Prism Pharma, Incyte Corp., Otsuka Pharmaceutical Co., Ltd., Bio-Path Holdings, Hybrigenics Corporation, Fusion Pharma LLC.

Myocardial Infarction Therapeutics Pipeline Analysis 2017 – Clinical Trials & Results, Patent and Other Developments

The myocardial infarction therapeutics pipeline is expected to increase in future due to rise in prevalence of myocardial infarction. Myocardial infarction is also commonly known as heart attack which is symptomatized by decrease in blood supply to the heart muscle due to coronary artery disease. According to American Heart Association, the mortality rate due to cardiovascular disease is higher than other disease. According to British Heart Foundation, in 2015, around 150,155 deaths, occurred due to cardiovascular disease in the U.K. Some of the drivers for the growth of the myocardial infarction therapeutics pipeline include increasing incidence of coronary artery disease, change in lifestyle, lack of exercise, increase in incidence of blood pressure and obesity. According to World Health Organization (WHO), there has been an increase in incidence of heart disease in smokers as compared to non-smokers.

Explore Report at:

The myocardial infarction is a state of blockage of flow of oxygen-rich blood to a section of heart muscle, leading to the death of muscle. Myocardial infarction most often occurs in case of coronary artery disease in which a waxy substance, known as plaque gets build up inside the coronary artery, decreasing the oxygen-rich blood supply to the heart. This condition is also known as atherosclerosis due to which area of plaque break open inside a coronary artery, leading to the formation of clot. This clot gets bigger with time and leads to the blockage of coronary artery. The heart failure is a condition in which heart cannot pump enough blood to meet the body need. In various cases, a discomfort occurs in the center or left side of the chest which can last for few minutes which goes away and comes back. The upper body discomfort and shortness of breath also occurs in case of cardiac disorders.

Request for Table of Content at:

Some of the key players having a pipeline of myocardial infarction therapeutics include Pfizer Inc., Novartis N.V., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, AstraZeneca, Apotex Inc., Par Pharmaceutical Companies, Inc., Sandoz, Mylan N.V.

Hemophilia Therapeutics Pipeline Analysis 2017 – Collaboration and Other Developments

The hemophilia therapeutics pipeline is expected to grow in future due to rise in prevalence of genetic variation. Hemophilia which is symptomatized by excessive bleeding in brains, joints, nose and mouth. Some of the drivers for the growth of the hemophilia therapeutics pipeline include increasing incidence of hemophilia, less number of drugs present for treatment of hemophilia.

Explore Report at:

Hemophilia is the disease, mostly inherited, in which people have little or no clotting factor. Clotting factor is required for normal blood clotting. These proteins work with platelets to promote the clotting of the blood. There are two types of hemophilia. Hemophilia A, in which clotting factor VIII is missing or present in very low level. Hemophilia B, in which clotting factor IX is missing or present in very low levels.

Most of the large pharma companies are spending in research and development for treatment of haemophilia, which are in clinical trials. Pfizer, Inc. is developing a gene therapy in collaboration with Spark Therapeutics, Inc., through SPK-FIX program for treatment of haemophilia, as a potential onetime therapy. SPK-9001 is a bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized, high-activity human factor IX variant, which was advanced using Spark’s proprietary technology. Chugai Pharmaceutical is developing a compound in collaboration with F. Hoffmann-La Roche AG, Emicizumab, which is considered as a Breakthrough Therapy by the US Food and Drug Administration. LFB USA, Inc. is introducing a biological, wich is recombinant Coagulation FVIIa for the treatment of haemophilia. Coagulation FVIIa is currently in Phase III clinical development stage. Alnylam Pharmaceuticals Inc. is developing a drug for the treatment of haemophilia, ALN-AT3SC, which lowers the level of plasma antithrombin. ALN-AT3SC drug led to restoration of homeostasis in people with haemophilia. OPKO Biologics Ltd. Is developing a drug MOD-5014, whih is a long-acting recombinant FVIIa for the treatment of hemophiia A or B. Octapharma AG is developing a compound fr the treatment of haemophilia, Wilate, which is stable, double virus inactivated, stable, highly purified concentrate of freeze-dried, active von Willebrand factor (VWF) and FVIII. Wilate is currently in Phase III clinical development. Novo Nordisk A/S is estimating a homeostatic effect of turoctocog alfa pegol, which is currently in Phase III. Bayer AG is developing a compound BAY1093884. BAY1093884 is an anti-TFPI antibody which is currently in Phase I. Shire Plc is developing a compound SHP656, which is currently in Phase I clinical development.

Request for Table of Content at:

Some of the key players having a pipeline of hemophilia therapeutics include Shire Plc, Biogen, Pfizer Inc., Novo Nordisk A/S, CSL Behring, F. Hoffmann-La Roche Ltd., Bayer AG, Biotest AG, Kedrion Biopharma Inc., and Octapharma AG.

Start-Stop Technology Market Trends, Size, Growth and Forecast to 2022

The study suggests that the global start stop technology market is likely to grow from $2,100.2 million in 2015 to $7,058.0 million by 2022. Stringent emission control norms, increasing need for fuel efficient vehicles and increasing adoption of hybrid vehicles are that factors that are expected to drive the demand for start-stop technology over the forecast period.

Explore Report at:

Insights on market segments

As per the findings of research, the enhanced starter was the largest contributor to the global start-stop technology market in 2015, in terms of volume and value; however, the integrated starter generator is expected to witness the highest growth, during the forecast period in terms of volume and value.

Enhanced starter and integrated starter generator-based start-stop systems are expected to dominate the market in future, and are expected to be used widely in passenger cars. Enhanced starter and integrated starter generator are more cost-effective and fuel efficient clean energy technologies as compared to direct starter and belt-driven alternator starter technologies.

Browse report Sample at:

Top six players account for major market share

The research states that the global start-stop technology market had a consolidated structure in 2015, where the top six competitors accounted for a major share of the market. Some of the key players in the global market include Robert Bosch GmbH, Continental AG, Denso Corporation, Delphi Automotive PLC, Johnson Controls, Inc, Hitachi, Ltd., Mitsubishi Electric Corporation, Valeo SA, and BorgWarner Inc.

Kaposi sarcoma Therapeutics Pipeline Analysis 2017 – Patent, Collaboration, and Other Developments

The kaposi sarcoma therapeutics pipeline is expected to grow rapidly as the disease also has the risk of the patient being infected with Acquired Immune Deficiency Syndrome (AIDS). AIDS is the most common risk factors of kaposi sarcoma, which develops in people who are infected with HIV. The Kaposi sarcoma therapeutics pipeline is expected to generate large revenue due to increasing awareness regarding cancer treatments, high demand for safe and effective medications, advancement in technologies and increasing prevalence of cancer and immunodeficiency syndrome. The American Cancer Society and other regulatory bodies are supporting the Kaposi sarcoma pipeline by providing increased funding and grants.

Explore Report at:

According to American Cancer Society, Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in the other parts of the body, such as in the lymph nodes (bean-sized collections of immune cells throughout the body), the lungs, or digestive tract. The abnormal cells of kaposi sarcoma form purple, red, or brown blotches or tumors on the skin. These affected areas are called lesions. The skin lesions of Kaposi sarcoma most often appear on the legs or face. They may look bad, but they usually cause no symptoms. At times, some lesions on the legs or in the groin area may cause the legs and feet to swell painfully.

Many companies have a pipeline of drugs for the treatment of Kaposi sarcoma, which are under clinical development. Vasgene Therapeutics, Inc plans to introduce a recombinant EphB4-HSA fusion protein, which is currently in Phase II. Recombinant EphB4-HSA fusion protein showed a promising result in blocking growth of blood vessels that provide blood to cancer. Apogee Biotechnology Corporation also plans to introduce a drug ABC294640, which is currently in Phase I clinical development for treatment of Kaposi sarcoma. Chiltern International Inc. plans to introduce a biological, XmAb13676, which is currently in Phase I clinical development. XmAb13676 is a monoclonal antibody expected to target CD20 expressing malignancies.

Request for Table of Content at:

Some of the companies having a pipeline of kaposi sarcoma therapeutics include Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffman-La Roche, AG, GlaxoSmithKline plc, Johnson & Johnson, Pfizer, Inc., and Merck & Co., Inc.

Gallbladder Cancer Therapeutics Pipeline Analysis 2017 – Clinical Trials & Results, Patent and Other Developments

Gallbladder cancer therapeutics pipeline is expected to witness increased growth in the future since very less number of drugs are available in the pipeline for the treatment of gallbladder cancer. There is an increase in awareness towards cancer treatments, increasing demand for safe and effective medicines, rising healthcare expenditure and technological advancements are supporting the growth of the gallbladder therapeutics pipeline.

Explore Report at:

 According to National Cancer Institute, a part of the U.S. National Institutes of Health, gallbladder cancer is a rare disease in which malignant cells are found in the tissues of the gallbladder. The gallbladder is a pear-shaped organ that lies just under the liver in the upper abdomen. The gallbladder stores bile, a fluid made by the liver to digest fat. When food is being broken down in the stomach and intestines, bile is released from the gallbladder through a tube called the common bile duct, which connects the gallbladder and liver to the first part of the small intestine. Women and native American are at higher risk for the gallbladder cancer due to estrogen replacement therapy and oral contraceptive use. The detection of the gallbladder cancer is complex until it has reaches its advanced stage and shows symptoms. Only about 1 of 5 gallbladder cancers is found in the early stages, when the cancer has not yet spread beyond the gallbladder.

The pipeline of gallbladder cancer therapeutics pipeline includes anti-PD-1 antibody BGB-A317. BeiGene, Ltd. is developing BGB-A317, a Phase I drug candidate that shows well-tolerated anti-tumor activity in gallbladder cancer and in other solid tumors. GlaxoSmithKline Plc plans to introduce a combination therapy of Gemcitabine-Pazopanib, which is currently in Phase II. Bayer AG plans to introduce a drug, copanlisib for treatment of gallbladder cancer, which is currently in Phase II clinical development. Eli Lilly and Company plans to introduce a drug LY2801653, which is also known as Merestinib. Merestinib is currently in Phase I clinical development against gallbladder cancer. Regorafenib which is in Phase II clinical development is also a pipeline drug from Bayer AG.

Request for Table of Content at:

According to the American Cancer Society, around 11,740 new cases for gall bladder cancer are estimated to be diagnosed, with 5,320 cases in men and 6,420 in women and around 3,830 deaths are expected to occur from the disease, 1,630 deaths in men and 2,200 deaths in women in the year 2017.

Some of the companies having a pipeline of gallbladder cancer therapeutics include 4SC AG, BeiGene Ltd., Eli Lilly and Company, Novartis AG and VasGene Therapeutics Inc.

Esophageal Cancer Therapeutics Market Development and Demand Forecast to 2023

Global esophageal cancer therapeutics market is expected to witness significant growth with an increasing awareness regarding cancer treatment and technological advancements. Also, high demand for safe and effective medications and rising prevalence of cancer are driving the growth of the global market. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing funding, designations and grants for speeding up the drug development process.

Explore Report at:

Esophageal cancer involves formation of malignant cells in the tissues of the esophagus. Esophagus is a muscular tube that enable food and liquids to move from the throat to the stomach. The main types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. Adenocarcinoma forms in cells that produce and release mucus and other fluids. Squamous cell carcinoma forms in flat cells lining the esophagus. Esophageal squamous cell carcinoma includes heavy alcohol consumption and smoking as major risk factors, with gastroesophageal reflux disease and Barrett esophagus further contributing as the risk factors of esophageal adenocarcinoma. Esophageal cancer has no early signs or symptoms; therefore, an advanced stage diagnosis is difficult.

Request for Table of Content at:

Some of the major drivers for the global esophageal cancer therapeutics market include combination therapies, treatment advancements, increasing number of regulatory approvals for esophageal cancer and a rise in the number of cancer treatment centers. Moreover, the launch of new drug therapies for esophageal cancer is expected to contribute as a key market driver in the near future. Also with a dense pipeline, many new drug candidates are expected to enter the global esophageal cancer therapeutics market. Safety concerns and efficacy of the treatment are the major factors that can hinder the market growth over the forecast period. Other factors hampering the market growth include low availability of drugs commercially and high cost of therapy for the treatment of esophageal cancer.

Some of the key players operating in the global esophageal cancer therapeutics market include Genentech, Inc., Sanofi-Aventis, Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., Merck & Co., Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, Gilead Sciences, and Bristol-Myers Squibb, among others.

Global Neuroendocrine Carcinoma Therapeutics Market Development, Growth and Forecast to 2023

Global neuroendocrine carcinoma therapeutics market is witnessing significant growth due to large number of marketed drugs and Phase III drugs. Neuroendocrine carcinoma is a tumor that begins in neuroendocrine cells and can spread, or metastasize, to other parts of the body. It starts in the hormone producing cells of the body’s neuroendocrine system. Neuroendocrine tumors can begin in many organs including, lungs, brain and gastrointestinal tract. It is a very rare cancer with symptoms such as hyperglycemia, hypoglycemia, diarrhea, weight loss, pain, cough, lump formation, jaundice, unusual bleeding, headache and anxiety. The risk factors of developing neuroendocrine cancer includes, age, gender, family history, immune system suppression, arsenic exposure and sun exposure. The diagnosis can be done by normal physical examination followed by blood tests, urine tests, X- ray, CT scan, PET scan, MRI and biopsy.

Explore Report at:

The treatments available for neuroendocrine tumor include chemotherapy, surgery and radiation therapy. Chemotherapy comprises the drug’s use to destroy malignant cells by hindering the cells ability to divide and grow. Streptozocin (Zanosar) and 5-fluorouracil (Adrucil, 5-FU) are some of the drugs that are used to treat neuroendocrine tumors. Many pharmaceutical companies have been working continuously for the development of targeted therapy for the growth of neuroendocrine cancer market.

Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for treatment of neuroendocrine cancer. Genentech Inc., F. Hoffmann-La Roche Ltd., Callisto Pharmaceuticals Pvt. Ltd. and BioSynthema, Inc. are some major companies that are determined to develop therapeutics for various neuroendocrine cancers. Lutathera, Atiprimod and Avastin are pipeline candidates that are presently being studied for their therapeutic efficacy in the treatment of neuroendocrine cancer. Also, there are many other pipeline drugs in Phase III which are expected to enter the neuroendocrine carcinoma therapeutics market in the future.

Request for Table of Content at:

Some of the key players operating in the global neuroendocrine carcinoma therapeutics market include Pfizer Ltd., Eli Lilly & Company, Novartis AG, F. Hoffmann-La Roche Ltd., Ispen SA, Amgen, Inc., Callisto Pharmaceuticals Pvt. Ltd., Biosynthema, Inc., Teva Pharmaceuticals, Ltd. and Bristol-Myers Squibb among others.